AFFiRiS was founded by Dr. Walter Schmidt (CEO) and Dr. Frank Mattner (CSO) in late 2003. Based on its business model and its globally unique expertise, AFFiRiS aims to initiate the clinical testing of a new vaccine against thus-far incurable diseases every 2 to 3 years.
Vienna (Austria), 5. June 2012. The worldwide first clinical trial for the development of a Parkinson’s vaccine has now been started by AFFiRiS AG.